An independent two-stage DCF analysis by a frontier AI model.
" data-astro-cid-3fhc5hvc> A conservative estimate for CVS. Despite its massive scale and diverse operations (Aetna, Caremark, Pharmacy), healthcare margins are under pressure. A 4% growth rate assumes they successfully navigate Medicare Advantage headwinds while capitalizing on their integrated care model.
" data-astro-cid-3fhc5hvc> The required return. With the 10-Year Treasury at 4.18%, a 9% discount rate implies an equity risk premium suitable for a mature, heavily regulated, but stable healthcare conglomerate like CVS.
" data-astro-cid-3fhc5hvc> 2% represents steady-state growth roughly mirroring long-term U.m. economic growth and inflation. We do not assume CVS will outpace general economic growth in perpetuity.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 1.0% | $12.13 | $10.40 | $9.10 | $8.09 | $7.28 |
| 1.5% | $13.24 | $11.20 | $9.71 | $8.56 | $7.66 |
| 2.0% | $14.56 | $12.13 | $10.40 | $9.10 | $8.09 |
| 2.5% | $16.18 | $13.24 | $11.20 | $9.71 | $8.56 |
| 3.0% | $18.20 | $14.56 | $12.13 | $10.40 | $9.10 |
■ Undervalued vs current price ■ Overvalued vs current price
Westmount Research. "CVS Health (CVS) Intrinsic Value: A DCF Analysis." westmountfundamentals.com, March 19, 2026.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.